Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid–paclitaxel (CLA-PTX) on B16-F10 melanoma

In the present study, we prepared a novel delivery system of iRGD (CRGDK/RGPD/EC)-modified sterically stabilized liposomes (SSLs) containing conjugated linoleic acid–paclitaxel (CLA-PTX). The anti-tumor effect of iRGD-SSL-CLA-PTX was investigated on B16-F10 melanoma in vitro and in vivo. The in vitro targeting effect of iRGD-modified SSLs was investigated in a real-time confocal microscopic analysis experiment. An endocytosis-inhibition assay was used to evaluate the endocytosis pathways of the iRGD-modified SSLs. In addition, the in vitro cellular uptake and in vitro cytotoxicity of iRGD-SSL-CLA-PTX were evaluated in B16-F10 melanoma cells. In vivo biodistribution and in vivo antitumor effects of iRGD-SSL-CLA-PTX were investigated in B16-F10 tumor-bearing mice. The induction of apoptosis by iRGD-SSL-CLA-PTX was evaluated in tumor-tissue sections. Real-time confocal microscopic analysis results indicated that the iRGD-modified SSLs internalized into B16-F10 cells faster than SSLs. The identified endocytosis pathway of iRGD-modified SSLs indicated that energy- and lipid raft-mediated endocytosis played a key role in the liposomes’ cellular uptake. The results of the cellular uptake experiment indicated that the increased cellular uptake of CLA-PTX in the iRGD-SSL-CLA-PTX-treated group was 1.9-, 2.4-, or 2.1-fold compared with that in the CLA-PTX group after a 2-, 4-, or 6-hour incubation, respectively. In the biodistribution test, the CLA-PTX level in tumor tissues from iRGD-SSL-CLA-PTX-treated mice at 1 hour (1.84±0.17 μg/g) and 4 hours (1.17±0.28 μg/g) was 2.3- and 2.0-fold higher than that of CLA-PTX solution at 1 hour (0.79±0.06 μg/g) and 4 hours (0.58±0.04 μg/g). The value of the area under the curve for the first 24 hours in the tumors of iRGD-SSL-CLA-PTX-treated mice was significantly higher than that in the SSL-CLA-PTX and CLA-PTX solution-treated groups (P<0.01). The in vivo antitumor results indicated that iRGD-SSL-CLA-PTX significantly inhibited the growth of B16-F10 tumors compared with the SSL-CLA-PTX or CLA-PTX solution-treatment groups (P<0.01). The results of tumor-cell apoptosis showed that tumors from the iRGD-SSL-CLA-PTX-treated group exhibited more advanced cell apoptosis compared with the control, CLA-PTX solution-, and SSL-CLA-PTX-treated groups. In conclusion, the antitumor effect of iRGD-SSL-CLA-PTX was confirmed on B16-F10 melanoma in vitro and in vivo.

[1]  F. Dosio,et al.  Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[2]  S. Baker,et al.  Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Qiang Zhang,et al.  Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings , 2012, International journal of nanomedicine.

[4]  Lin Mei,et al.  Paclitaxel drug delivery systems , 2013, Expert opinion on drug delivery.

[5]  K. Wasan,et al.  A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Yingjin Yuan,et al.  Synthesis and evaluation of water-soluble paclitaxel prodrugs. , 2002, Bioorganic & medicinal chemistry letters.

[7]  Richard B Greenwald,et al.  Effective drug delivery by PEGylated drug conjugates. , 2003, Advanced drug delivery reviews.

[8]  Jie Tang,et al.  A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. , 2013, Biomaterials.

[9]  Erkki Ruoslahti,et al.  Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.

[10]  Qiang Zhang,et al.  The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation , 2013, International journal of nanomedicine.

[11]  R. Mumper,et al.  2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer. , 2013, Cancer letters.

[12]  R. Kok,et al.  Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. , 2013, Advanced drug delivery reviews.

[13]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[14]  Marilena Loizidou,et al.  Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. , 2009, Trends in pharmacological sciences.

[15]  G. Battaglia,et al.  Endocytosis at the nanoscale. , 2012, Chemical Society reviews.

[16]  Baorui Liu,et al.  The effect of hydrophilic chain length and iRGD on drug delivery from poly(ε-caprolactone)-poly(N-vinylpyrrolidone) nanoparticles. , 2011, Biomaterials.

[17]  D. Yan,et al.  Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery. , 2011, Biomacromolecules.

[18]  Kazuo Maruyama,et al.  Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. , 2011, Advanced drug delivery reviews.

[19]  M. Skwarczynski,et al.  A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel. , 2003, Journal of medicinal chemistry.

[20]  Hao Bai,et al.  Effect of molecular weight of PGG-paclitaxel conjugates on in vitro and in vivo efficacy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Xin-guo Jiang,et al.  Quantum dots for tracking cellular transport of lectin-functionalized nanoparticles. , 2008, Biochemical and biophysical research communications.

[22]  K. Sakai-Kato,et al.  Intracellular trafficking mechanism, from intracellular uptake to extracellular efflux, for phospholipid/cholesterol liposomes. , 2012, Biomaterials.

[23]  J. Singer,et al.  Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer–drug conjugate , 2006, International journal of nanomedicine.

[24]  R. Zhang,et al.  Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Meng Huang,et al.  Mechanisms of transcellular transport of wheat germ agglutinin-functionalized polymeric nanoparticles in Caco-2 cells. , 2012, Biomaterials.

[26]  F. Kratz,et al.  Anticancer carrier-linked prodrugs in clinical trials , 2007, Expert opinion on investigational drugs.

[27]  Quanyin Hu,et al.  PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. , 2013, Biomaterials.

[28]  Qiang Zhang,et al.  Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. , 2013, Biomaterials.

[29]  J. Ziello,et al.  Cellular Endocytosis and Gene Delivery , 2010, Molecular medicine.

[30]  G. Gregoriadis.  Liposomes in biology and medicine , 1978, Nature.

[31]  X. Liu,et al.  iRGD-coupled responsive fluorescent nanogel for targeted drug delivery. , 2013, Biomaterials.

[32]  V. Préat,et al.  RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. , 2012, Molecular pharmaceutics.

[33]  S. Niimura,et al.  Characterization of vascular permeability-increasing component isolated from solid tumors and the effect of highly polymerized dextran sulfate on its activity. , 1986, Japanese journal of pharmacology.

[34]  Xinguo Jiang,et al.  Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. , 2011, Biomaterials.

[35]  T. Park,et al.  Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. , 2008, Bioconjugate chemistry.

[36]  I. Zuhorn,et al.  Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. , 2004, The Biochemical journal.

[37]  R. Panchagnula,et al.  Preparation and characterization of water-soluble prodrug, liposomes and micelles of Paclitaxel. , 2005, Current drug delivery.

[38]  X. Wang,et al.  Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles. , 2013, Biomaterials.

[39]  H. Long.  Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. , 1994, Mayo Clinic proceedings.

[40]  Quanyin Hu,et al.  The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. , 2013, Biomaterials.

[41]  Jian Song,et al.  A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. , 2014, Biomaterials.

[42]  Qiang Zhang,et al.  The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat. , 2010, Biomaterials.

[43]  R. Prud’homme,et al.  Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. , 2008, Journal of medicinal chemistry.